2. Cell Cycle/DNA Damage
  3. CDK
  4. CDK7-IN-27

CDK7-IN-27 (Compound 37) is a selective inhibitor for cyclin-dependent kinase 7 (CDK7), with Ki of 3 nM. CDK7-IN-27 arrests the cell cycle at G0/G1 phase.

For research use only. We do not sell to patients.

CDK7-IN-27 Chemical Structure

CDK7-IN-27 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

CDK7-IN-27 Related Antibodies

Top Publications Citing Use of Products

View All CDK Isoform Specific Products:

View All Isoforms

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

CDK7-IN-27 (Compound 37) is a selective inhibitor for cyclin-dependent kinase 7 (CDK7), with Ki of 3 nM. CDK7-IN-27 arrests the cell cycle at G0/G1 phase[1].

IC50 & Target

CDK7

3 nM (IC50)

CDK2

19.4 nM (IC50)

In Vitro

CDK7-IN-27 (0.04-10 μM, 5 days) inhibits proliferations of MDA-MB-453 cells with EC50 of 1.49 μM[1].
CDK7_IN-27 (1 μM, 24 h) exhibits good metabolic stability in liver microsomes in mouse and human , with a half-time of 38.5 min and 34.1 min[1].
CDK7_IN-27 (0-1 μM, 24 h) suppresses the phosphorylation of retinoblastoma (Rb) protein through CDK7 inhibition, and thus arrests the cell cycle at G0/G1 phase[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CDK7-IN-27 Related Antibodies

Western Blot Analysis[1]

Cell Line: MDA-MB-453
Concentration: 0-1 μM
Incubation Time: 24 h
Result: Inhibited phosphorylation of Rb protein at Ser780, 807/811, and Thr826.

Cell Viability Assay[1]

Cell Line: MDA-MB-453
Concentration: 0.04-10 μM
Incubation Time: 5 days
Result: Suppressed the cancer cell proliferation.
Molecular Weight

479.62

Formula

C26H37N7O2
SMILES

CC(C1=C2N=C3N=C(N2N=C1)NCC4=CC=CC=C4OC[C@H](CCCC5(CN3)CCNCC5)O)C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

CDK7-IN-27 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

CDK7-IN-27CDKCyclin dependent kinaseMDA-MB-453TNBCtriple-negative breast cancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
CDK7-IN-27
Cat. No.:
HY-162416
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.